Applications of Gage Reproducibility & Repeatability (GRR): Understanding and Quantifying the Effect of Variations from Different Sources on a Robust Process Development
暂无分享,去创建一个
A. K. Roy | G. R. Deshpande | Amrendra Kumar Roy | A. Deshpande | Girish R. Deshpande | Amol A. Deshpande | Ayyalasomayajula Ramya | Vavilala Vishweshwar | A. Ramya | Vavilala Vishweshwar
[1] Douglas C. Montgomery,et al. GAUGE CAPABILITY AND DESIGNED EXPERIMENTS. PART I: BASIC METHODS , 1993 .
[2] I. Houson. Process Understanding: For Scale-Up and Manufacture of Active Ingredients , 2011 .
[3] E. Kellenbach,et al. Applying QbD Principles To Develop a Generic UHPLC Method Which Facilitates Continual Improvement and Innovation Throughout the Product Lifecycle for a Commercial API , 2013 .
[4] S Furlanetto,et al. How experimental design can improve the validation process. Studies in pharmaceutical analysis , 2003, Analytical and bioanalytical chemistry.
[5] Thomas Dowling,et al. Use of a quality-by-design approach to justify removal of the HPLC weight % assay from routine API stability testing protocols. , 2009, Journal of pharmaceutical and biomedical analysis.
[6] S. Provera,et al. Development of a Dynamic Kinetic Resolution for the Isolation of an Intermediate in the Synthesis of Casopitant Mesylate: Application of QbD Principles in the Definition of the Parameter Ranges, Issues in the Scale-Up and Mitigation Strategies , 2010 .
[7] Roger Nosal,et al. API Quality by Design Example from the Torcetrapib Manufacturing Process , 2007, Journal of Pharmaceutical Innovation.
[8] Bernard A Olsen,et al. Is HPLC assay for drug substance a useful quality control attribute? , 2007, Journal of pharmaceutical and biomedical analysis.
[9] Zadeo Cimarosti,et al. Application of the QbD Principles in the Development of the Casopitant Mesylate Manufacturing Process. Process Research Studies for the Definition of the Control Strategy of some Drug Substance-CQAs for Stages 2a, 2b, and 2c , 2010 .
[10] D. Montgomery,et al. Design and analysis of gauge R&R studies : making decisions with confidence intervals in random and mixed ANOVA models , 2005 .
[11] David Q. Liu,et al. A Systematic Method Development Strategy for Determination of Pharmaceutical Genotoxic Impurities , 2010 .
[12] A. K. Roy,et al. Rapid Screening of Volatile Ion-Pair Reagents Using UHPLC and Robust Analytical Method Development Using DoE for an Acetyl Cholinesterase Inhibitor: Galantamine HBr , 2011 .
[13] Y Vander Heyden,et al. Improving method capability of a drug substance HPLC assay. , 2006, Journal of pharmaceutical and biomedical analysis.
[14] D. Snodin. Genotoxic Impurities: A Regulatory Toxicology Commentary on Recent Articles in Organic Process Research & Development , 2011 .
[15] A. K. Roy,et al. Controlling the Exothermicity of O-Arylation by Evaporative Cooling during the Process Development of Fluoxetine Hydrochloride , 2014 .
[16] A. K. Roy,et al. Acetic anhydride-promoted one-pot condensation of 2,4-thiazolidinedione with bisulfite adducts of aldehydes , 2014 .